Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients

This publication has 23 references indexed in Scilit:

• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
  Annals of Oncology, 2010
• Palonosetron
  Drugs, 2009
• ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
  Journal of Clinical Oncology, 2009
• Chemotherapy-Induced Nausea and Vomiting
  New England Journal of Medicine, 2008
• ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi
  Journal of Clinical Oncology, 2005
• Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
  Journal of Clinical Oncology, 2005
• Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study.
  Journal of Clinical Oncology, 1997
• Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
  Journal of Clinical Oncology, 1991
• Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.
  BMJ, 1984
• Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
  Cancer, 1975